Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?
Bani-Sadr
Firouzé
F
Denoeud
Lise
L
Morand
Patrice
P
Lunel-Fabiani
Françoise
F
Pol
Stanislas
S
Cacoub
Patrice
P
Perronne
Christian
C
Carrat
Fabrice
F
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D001663:Bilirubin / Q000097:blood; D016009:Chi-Square Distribution; D015224:Dideoxynucleosides / Q000627:therapeutic use*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006678:HIV; D015658:HIV Infections / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D006526:Hepatitis C / Q000097:blood / Q000150:complications* / Q000188:drug therapy* / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D015999:Multivariate Analysis; D012367:RNA, Viral / Q000097:blood; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D013997:Time Factors; D017211:Treatment Failure; D019562:Viral Load; D000099227:Abacavir
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D001663:Bilirubin; D015224:Dideoxynucleosides; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D012254:Ribavirin; D000099227:Abacavir